A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies

作者:Zhou, Chuchu; Guo, Chenqi; Li, Wenhao; Zhao, Juan; Yang, Qin; Tan, Tiantian; Wan, Zhuoya; Dong, Jianxia; Song, Xu*; Gong, Tao*
来源:Drug Development and Industrial Pharmacy, 2018, 44(12): 2005-2012.
DOI:10.1080/03639045.2018.1506475

摘要

It is necessary to discover a novel antitumor liposome with prolonged circulation time, high efficacy, and low cost. Here, we reported a liposomal honokiol (HNK) prepared with a new type of excipient, Kolliphor HS15, which was termed as HS15-LP-HNK. In addition, we employed PEGylated liposomal honokiol (PEG-LP-HNK) as positive control. The HS15-LP-HNK was prepared by thin-film hydration method. It was near-spherical morphology with an average size of 80.62 +/- 0.72 nm (PDI = 0.234 +/- 0.007) and a mean zeta potential of -3.91 +/- 0.06 mv. In vivo studies exhibited no significant difference between HS15-LP-HNK and PEG-LP-HNK. The pharmacokinetic and biodistribution results showed that HS15-LP-HNK could improve the bioavailability and increase tumor accumulation of honokiol. Furthermore, HS15-LP-HNK could enhance antitumor efficacy of honokiol with low toxicity. In summary, HS15-LP-HNK is promising in tumor targeted drug delivery system.